Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

Author:

Abramson Jeremy S.1,Gordon Leo I.2,Palomba Maria Lia3,Lunning Matthew Alexander4,Arnason Jon E.5,Forero-Torres Andres6,Wang Michael7,Maloney David G.8,Sehgal Alison9,Andreadis Charalambos10,Purev Enkhtsetseg11,Solomon Scott R.12,Ghosh Nilanjan13,Albertson Tina M.14,Xie Benhuai14,Garcia Jacob15,Siddiqi Tanya16

Affiliation:

1. Massachusetts General Hospital Cancer Center, Boston, MA;

2. Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL;

3. Memorial Sloan Kettering Cancer Center, New York, NY;

4. University of Nebraska Medical Center, Omaha, NE;

5. Beth Israel Deaconess Medical Center, Boston, MA;

6. University of Alabama at Birmingham, Birmingham, AL;

7. The University of Texas MD Anderson Cancer Center, Houston, TX;

8. Fred Hutchinson Cancer Research Center, Seattle, WA;

9. University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA;

10. University of California, San Francisco, San Francisco, CA;

11. National Institutes of Health, Bethesda, MD;

12. BMT Group of Georgia, Atlanta, GA;

13. Carolinas Healthcare, Charlotte, NC;

14. Juno Therapeutics, Inc., Seattle, WA;

15. Juno Therapeutics, Seattle, WA;

16. City of Hope National Medical, Duarte, CA;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3